ライフサイエンスコーパス: cotreat

1 rom cells treated with TCDD or TCDD plus E2 (cotreated).

2 specific T cells could only be isolated from cotreated animals.

3 els of BR96 sFv-PE40 relative to non-CTLA4Ig-cotreated animals.

4 We then established that only cotreated cells induced an efficient tumor-specific T-ce

5 Consistent with the above data, LT-cotreated cells show elevated phosphorylation of two IKK

6 Death seems to be induced in cotreated cells through an accumulation of persistent do

7 tially blocked apoptosis in DHA and butyrate cotreated cells.

8 ear extracts from CHX-treated and CHX + TCDD cotreated cultures formed approximately 58 and approxima

9 addition, only when mice were immunized with cotreated dead tumor cells could they be protected (vacc

10 54 children who initiated ART, 99 (39%) were cotreated for tuberculosis during follow-up.

11 Children who were not cotreated for tuberculosis were more likely to achieve v

12 By 4 wk, IL-16/IL-2-cotreated PBMC cultures were predominantly CD4+, CD25+ C

13 position was observed in livers from LPS/RAN-cotreated rats 3 and 6 hours after RAN.

14 c acid, which was most pronounced in LPS/RAN-cotreated rats, suggested altered sinusoidal endothelial

15 oing allograft rejection could be rescued by cotreating recipients with neutralizing anti-IL-10 antib

16 i-BR96-sFv-PE40 Abs was decreased in CTLA4Ig-cotreated rodents and dogs resulting in increased plasma

17 visible light (>420 nm) photocurrent of the cotreated TiO(2) is 0.16 mA/cm(2) and accounts for 41% o

18 ctivity of the hydrogenation and nitridation cotreated TiO(2) NW arrays.

19 n, doxorubicin, or cyclophosphamide and were cotreated with AAV9-MIS, recombinant MIS protein, or veh

20 did not affect neurabin-null mice or WT mice cotreated with an RGS4 inhibitor.

21 When anti-CTLA-4 mAb-treated mice were cotreated with anti-CD3 mAb (teplizumab), hepatitis and

22 addition, the ALT activity in PD-1(-/-) mice cotreated with anti-CTLA4 antibody and AQ did not return

23 d when primary cultured rat hepatocytes were cotreated with any of the following agents that inhibit

24 In contrast, a bladder cancer cell line cotreated with ATM and replication inhibitors progressed

25 and these responses were attenuated in cells cotreated with BITC plus glutathione (GSH).

26 Exposure of NTUB1 cells to 4 cotreated with cisplatin for significantly decreased the

27 2 therapy was not reduced compared with IL-2 cotreated with CNI-1493.

28 doses of 1 nM, and when fetal cultures were cotreated with CRH, ACTH was induced five- to sixfold as

29 d IP-10 mRNA expression was blocked in cells cotreated with cycloheximide.

30 TN4 cells were transfected with pGRE.Luc and cotreated with dexamethasone, with and without the compe

31 y due to limiting levels of ERalpha in cells cotreated with E plus TCDD.

32 ion, and this response is inhibited in cells cotreated with E2 plus TCDD.

33 Human chondrocytes cotreated with EGCG produced significantly less NO compa

34 In cells cotreated with fluasterone, however, there was a dose-de

35 In contrast, anoxic neurons cotreated with GABA(A+B)R antagonists underwent seizure-

36 -33 augmented IL-13 secretion from basophils cotreated with IL-3, with minimal effects on histamine a

37 y fibrin deposition occurs in livers of rats cotreated with LPS/RAN.

38 When larvae were cotreated with LWamide and the 5-HT antagonist ketanseri

39 Cultures cotreated with MGd and zinc acetate displayed further in

40 ted by enhanced apoptosis induction in cells cotreated with Nutlin-3a and the nuclear export inhibito

41 ned from animals treated with PEITC alone or cotreated with PEITC + NMBA were more similar to control

42 Subgroups were cotreated with pharmacologic ER-antagonist or with inhib

43 Complementary studies were performed in rats cotreated with selective ERalpha- or ERbeta-antagonist.

44 In animals cotreated with TAM + 6-MCDF at doses of 100, 50, or 25 m

45 henicol acetyltransferase activity; in cells cotreated with TCDD plus E2 the induced response was not

46 d AhR loss and enhanced AhR loss in cultures cotreated with TCDD.

47 eased when p53 wild-type (p53(wt)) GBMs were cotreated with the active form of p53 inhibitor, and thi

48 ulate cell cycle traverse when cultures were cotreated with the potent cdk2 inhibitor roscovitine.

49 inhibitors MG132 and PSII, but not in cells cotreated with the protease inhibitors calpain II and ca

50 by PPARgamma agonists was inhibited in cells cotreated with the proteasome inhibitors MG132 and PSII,

51 milar outcome was observed in wild-type mice cotreated with the TLR ligands and cobra venom factor, a

52 acceptable concentrations of As(2)O(3) when cotreated with these GPx and catalase inhibitors.

53 roarray analysis revealed that human B cells cotreated with these reagents resulted in only approxima

54 Interestingly, cotreating with LT differentially affects the ET-induced